About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
Dec 16, 2020... REHOVOT, ISRAEL—December 16, 2020—Cancers like melanoma are hard to treat, not least because they have a varied bag of tricks for defeating or evading treatments. Now, a combined research effort by the Weizmann Institute of Science, the Netherlands Cancer Institute in Amsterdam, and the University of Oslo shows exactly how tumors, in their fight to survive, will go so far as to starve themselves in order to keep the immune cells that would eradicate them from functioning. The work was published in Nature.
https://www.weizmann-usa.org/news-media/news-releases/bacteria-may-aid-anti-cancer-immune-response/
Mar 17, 2021... REHOVOT, ISRAEL—March 17, 2021—Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. In a new study published in Nature, researchers at the Weizmann Institute of Science and their collaborators have discovered that the immune system “sees” these bacteria and shown that they can be harnessed to provoke an immune reaction against the tumor. The study may also help clarify the connection between immunotherapy and the gut microbiome, explaining the findings of previous research showing that the microbiome affects the success of immunotherapy.
Mar 17, 2021...
Cancer cells present bacterial peptides on the outside of their walls, marking them as a foreign element to the body’s immune system, Weizmann Institute scientists report in a new article published in Nature.
This is crucial as while immunotherapy has been able to help melanoma cancer patients in roughly 40% of cases, the new findings could pave the road to more effective treatments and many lives saved in the future.
https://www.weizmann-usa.org/news-media/news-releases/the-triple-threat-of-coronavirus/
May 12, 2021... REHOVOT, ISRAEL—May 12, 2021—Severe symptoms of COVID-19, leading often to death, are thought to result from the patient’s own acute immune response rather than from damage inflicted directly by the virus. Intensive research efforts are therefore seeking to determine how the SARS-CoV-2 virus manages to mount an effective invasion while throwing the immune system off course. A new study, published in Nature, reveals a multipronged strategy that the virus employs to ensure its quick and efficient replication, while avoiding detection by the immune system. The study, conducted jointly by the research groups of Dr. Noam Stern-Ginossar at the Weizmann Institute of Science and Dr. Nir Paran and Dr. Tomer Israely of the Israel Institute for Biological, Chemical and Environmental Sciences, focused on understanding the molecular mechanisms at work during infection by SARS-CoV-2 at the cellular level.
May 12, 2021...
COVID-19 is so dangerous because the virus uses a three-pronged attack mechanism to stop cells from quickly triggering the immune system, Israeli scientists have concluded.
They offer a portrait of how exactly the SARS-CoV-2 virus behaves once inside human cells — they say it’s the most detailed to date — in an article published on Wednesday in the peer-reviewed journal Nature.
After hundreds of hours in their labs monitoring the virus interacting with cells, they have concluded that the virus mounts a hostile takeover on the cell’s protein-making machinery, and stops it from making proteins needed to galvanize the immune system.
May 14, 2021... The American Committee’s Women for Science (W4S) initiative hosted an engaging webinar, featuring two leading neuroscientists: Weizmann Institute President Prof. Alon Chen and Prof. Michal Schwartz of the Department of Neurobiology. Following introductory remarks by W4S Co-Chair Ellen Merlo, Prof. Chen provided an overview Weizmann’s flagship Institute for Brian and Neural Sciences. Featured speaker Prof. Michal Schwartz then presented her trailblazing research, based on her groundbreaking discoveries about the connection between the immune system and the brain. Her innovative work is paving the way to a revolutionary platform for the treatment of Alzheimer’s and age-related dementia. To conclude the program, Prof. Schwartz participated in a dynamic Q&A, moderated by Ellen Merlo.
May 19, 2021... REHOVOT, ISRAEL—May 19, 2021—Our livers work hard to perform a significant range of activities: helping us digest food, maintaining body temperature, and serving as an important checkpoint of the immune system for everything that we eat. It is inside the liver that the unique, rich, and complex network of immune cells and pathways is set up to decide whether a food particle is harmless or a dangerous pathogen that should be neutralized and removed. The liver is, therefore, very sensitive to the food we consume, and sometimes a poor diet can induce a serious dysregulation of the immune activities within it.
Dec 09, 2021... REHOVOT, ISRAEL—December 9, 2021—An exclusive “license” for making insulin in the human body belongs to the beta cells scattered throughout the pancreas. But because beta cells can become scarce or dysfunctional in people with diabetes, scientists have been searching for other cells that might be coaxed into manufacturing the vital glucose-regulating hormone. In a study published today in Nature Medicine, researchers from the Weizmann Institute of Science and from Yale School of Medicine discovered insulin-making cells in an unexpected place, the fetal intestine. This discovery may open up new directions in the future development of potential treatments for diabetes.
Feb 18, 2022... REHOVOT, ISRAEL—February 18, 2022—Even after prevailing over a viral infection, our immune system stays active, protecting us from any lingering viruses or recurring disease. But what happens if we pick up a bacterial infection – say, salmonella food poisoning from take-out chicken soup – while recovering from flu or COVID-19? A new study at the Weizmann Institute of Science published today in Immunity, shows that in such cases, the immune system has a clever way of setting priorities, one that might be exploited for the development of future therapies against autoimmune diseases.
Apr 04, 2022... REHOVOT, ISRAEL—April 4, 2022—Supporting actors sometimes steal the show. In a new study published today in Cell, researchers headed by Prof. Ido Amit at the Weizmann Institute of Science have shown that supporting cells called fibroblasts, long viewed as uniform background players, are in fact extremely varied and vital. A subset of these cells, according to the study, may lie at the origins of scleroderma—a rare autoimmune disease. The findings open a new direction for developing a future therapy against this devastating, incurable disorder.
©2023 American Committee for the Weizmann Institute of Science
